Business
HI-PEITHO trial demonstrates Boston Scientific EKOS™ Endovascular System is superior to standard of care for treatment of acute pulmonary embolism
Boston Scientific Corporation (NYSE: BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating that the EKOS system plus anticoagulation was superior to the current standard of care – anticoagulation alone – for the treatment of acute PE. Findings from the trial were presented in a late-b
About this update from Boston Scientific Corporation
[{"type":"text","content":"Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone","length":215,"tagName":"p","attribs":{}},{"type":"text","content":"Late breaking findings presented at ACC.26 and simultaneously published in The New England Journal of Medicine","length":110,"tagName":"p","attribs":{}},{"type":"text","content":"MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive data from the HI-PEITHO global randomized clinical trial evaluating the use of the EKOS™ Endovascular System in patients with intermediate-risk pulmonary embolism (PE). The study met the composite primary endpoint, with data demonstrating that the EKOS system plus anticoagulation was superior to the current standard of care – anticoagulation alone – for the treatment of acute PE. Findings from the trial were presented in a late-breaking science session at the American College of Cardiology's Annual Scientific Session & Expo and simultaneously published in The New England Journal of Medicine.","length":740,"tagName":"p"},{"type":"image","alt":"EKOS™ Endovascular System","displaySize":"","headline":null,"caption":"EKOS™ Endovascular System","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":309,"url":"https://media.zenfs.com/en/prnewswire.com/4ee6608920f27344abb8b1a9cafad732"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wW.vuwC03x5mTd_csgxvdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTU0NQ--/https://media.zenfs.com/en/prnewswire.com/4ee6608920f27344abb8b1a9cafad732","width":400,"height":309}},"href":"https://mma.prnewswire.com/media/2944763/EKOS__Acoustic_Pulse_Thrombolysis_Treatment_Boston_Scientific.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"PE is a blood clot that causes a blockage in one or more pulmonary arteries that bring blood to the lungs, and is the third leading cause of cardiovascular mortality.1 Current medical guidelines for treating PE recommend medical management with anticoagulation as the standard of care for patients at all risk levels. A minimally invasive intervention, the EKOS system delivers a low dose of clot-dissolving medication directly to th...